265 related articles for article (PubMed ID: 31046707)
21. Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus.
Bixler SL; Bocan TM; Wells J; Wetzel KS; Van Tongeren SA; Garza NL; Donnelly G; Cazares LH; Soloveva V; Welch L; Epstein C; Liang LF; Giesing D; Lenk R; Bavari S; Warren TK
Antiviral Res; 2018 Mar; 151():50-54. PubMed ID: 29289664
[TBL] [Abstract][Full Text] [Related]
22. Ebola Virus Infection: Review of the Pharmacokinetic and Pharmacodynamic Properties of Drugs Considered for Testing in Human Efficacy Trials.
Madelain V; Nguyen TH; Olivo A; de Lamballerie X; Guedj J; Taburet AM; Mentré F
Clin Pharmacokinet; 2016 Aug; 55(8):907-23. PubMed ID: 26798032
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and viral kinetics in a rapidly cured patient with Ebola virus disease: a case report.
Schibler M; Vetter P; Cherpillod P; Petty TJ; Cordey S; Vieille G; Yerly S; Siegrist CA; Samii K; Dayer JA; Docquier M; Zdobnov EM; Simpson AJH; Rees PSC; Sarria FB; Gasche Y; Chappuis F; Iten A; Pittet D; Pugin J; Kaiser L
Lancet Infect Dis; 2015 Sep; 15(9):1034-1040. PubMed ID: 26201298
[TBL] [Abstract][Full Text] [Related]
24. Modelling Ebola virus dynamics: Implications for therapy.
Martyushev A; Nakaoka S; Sato K; Noda T; Iwami S
Antiviral Res; 2016 Nov; 135():62-73. PubMed ID: 27743917
[TBL] [Abstract][Full Text] [Related]
25. A 6-Year-Old Child with Severe Ebola Virus Disease: Laboratory-Guided Clinical Care in an Ebola Treatment Center in Guinea.
Palich R; Gala JL; Petitjean F; Shepherd S; Peyrouset O; Abdoul BM; Kinda M; Danel C; Augier A; Anglaret X; Malvy D; Blackwell N;
PLoS Negl Trop Dis; 2016 Mar; 10(3):e0004393. PubMed ID: 27011342
[No Abstract] [Full Text] [Related]
26. Effect of anti-Ebola virus monoclonal antibodies on endogenous antibody production in survivors of Ebola virus disease in the Democratic Republic of the Congo: an observational cohort study.
Nkuba-Ndaye A; Dilu-Keti A; Tovar-Sanchez T; Diallo MSK; Mukadi-Bamuleka D; Kitenge R; Formenty P; Legand A; Edidi-Atani F; Thaurignac G; Pelloquin R; Mbala-Kingebeni P; Toure A; Ayouba A; Muyembe-Tamfum JJ; Delaporte E; Peeters M; Ahuka-Mundeke S;
Lancet Infect Dis; 2024 Mar; 24(3):266-274. PubMed ID: 38043556
[TBL] [Abstract][Full Text] [Related]
27. Clinical Evaluation of Ebola Virus Disease Therapeutics.
Liu G; Wong G; Su S; Bi Y; Plummer F; Gao GF; Kobinger G; Qiu X
Trends Mol Med; 2017 Sep; 23(9):820-830. PubMed ID: 28822631
[TBL] [Abstract][Full Text] [Related]
28. Infectious diseases. Ebola drug trials lurch ahead.
Kupferschmidt K; Cohen J
Science; 2015 Feb; 347(6223):701-2. PubMed ID: 25678637
[No Abstract] [Full Text] [Related]
29. Antiviral therapeutics for the treatment of Ebola virus infection.
Cardile AP; Downey LG; Wiseman PD; Warren TK; Bavari S
Curr Opin Pharmacol; 2016 Oct; 30():138-143. PubMed ID: 27639220
[TBL] [Abstract][Full Text] [Related]
30. [Recent Advances in Vaccines and Drugs Against the Ebola Virus].
Zhu X; Yao C; Wei Y; Kou Z; Hu K
Bing Du Xue Bao; 2015 May; 31(3):287-92. PubMed ID: 26470536
[TBL] [Abstract][Full Text] [Related]
31. Ebola virus dynamics in mice treated with favipiravir.
Madelain V; Oestereich L; Graw F; Nguyen TH; de Lamballerie X; Mentré F; Günther S; Guedj J
Antiviral Res; 2015 Nov; 123():70-7. PubMed ID: 26343011
[TBL] [Abstract][Full Text] [Related]
32. QTc interval prolongation during favipiravir therapy in an Ebolavirus-infected patient.
Chinello P; Petrosillo N; Pittalis S; Biava G; Ippolito G; Nicastri E;
PLoS Negl Trop Dis; 2017 Dec; 11(12):e0006034. PubMed ID: 29283993
[No Abstract] [Full Text] [Related]
33. Epidemiological characteristics, clinical manifestations, and treatment outcome of 139 paediatric Ebola patients treated at a Sierra Leone Ebola treatment center.
Kangbai JB; Heumann C; Hoelscher M; Sahr F; Froeschl G
BMC Infect Dis; 2019 Jan; 19(1):81. PubMed ID: 30678649
[TBL] [Abstract][Full Text] [Related]
34. Challenges in preparing and implementing a clinical trial at field level in an Ebola emergency: A case study in Guinea, West Africa.
Carazo Perez S; Folkesson E; Anglaret X; Beavogui AH; Berbain E; Camara AM; Depoortere E; Lefevre A; Maes P; Malme KN; Malvy JD; Ombelet S; Poelaert G; Sissoko D; Tounkara A; Trbovic P; Piguet P; Antierens A
PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005545. PubMed ID: 28640812
[TBL] [Abstract][Full Text] [Related]
35. Ebola virus disease complicated with viral interstitial pneumonia: a case report.
Petrosillo N; Nicastri E; Lanini S; Capobianchi MR; Di Caro A; Antonini M; Puro V; Lauria FN; Shindo N; Magrini N; Kobinger GP; Ippolito G;
BMC Infect Dis; 2015 Oct; 15():432. PubMed ID: 26471197
[TBL] [Abstract][Full Text] [Related]
36. Experimental Treatment of Ebola Virus Disease with Brincidofovir.
Dunning J; Kennedy SB; Antierens A; Whitehead J; Ciglenecki I; Carson G; Kanapathipillai R; Castle L; Howell-Jones R; Pardinaz-Solis R; Grove J; Scott J; Lang T; Olliaro P; Horby PW;
PLoS One; 2016; 11(9):e0162199. PubMed ID: 27611077
[TBL] [Abstract][Full Text] [Related]
37. Repurposed therapeutic agents targeting the Ebola virus: a protocol for a systematic review.
Sweiti H; Ekwunife O; Jaschinski T; Lhachimi SK
Syst Rev; 2015 Nov; 4():171. PubMed ID: 26607658
[TBL] [Abstract][Full Text] [Related]
38. Treatment-focused Ebola trials, supportive care and future of filovirus care.
Keshtkar-Jahromi M; Martins KAO; Cardile AP; Reisler RB; Christopher GW; Bavari S
Expert Rev Anti Infect Ther; 2018 Jan; 16(1):67-76. PubMed ID: 29210303
[TBL] [Abstract][Full Text] [Related]
39. Evaluating clinical trial designs for investigational treatments of Ebola virus disease.
Cooper BS; Boni MF; Pan-ngum W; Day NP; Horby PW; Olliaro P; Lang T; White NJ; White LJ; Whitehead J
PLoS Med; 2015 Apr; 12(4):e1001815. PubMed ID: 25874579
[TBL] [Abstract][Full Text] [Related]
40. [Current status of drug treatment against the disease caused by the Ebola virus].
Reina J
Rev Esp Quimioter; 2016 Feb; 29(1):1-7. PubMed ID: 26785224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
